US OptionsDetailed Quotes
AMGN240712C307500
- 24.50
- +20.25+476.47%
15min DelayClose Jul 12 15:59 ET
25.93High23.40Low
23.40Open4.25Pre Close7 Volume20 Open Interest307.50Strike Price17.47KTurnover0.00%IV0.35%PremiumJul 12, 2024Expiry Date23.33Intrinsic Value100Multiplier-1DDays to Expiry1.17Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma14.21Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Amgen Stock Discussion
FDA approves Blincyto® for a specific type of leukemia* in consolidation phase
*CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)
» Blincyto® + chemo cuts death risk by 58% in consolidation phase 👏
» superior survival vs. chemo alone
» 1st BiTE® therapy for consolidation, regardless of MRD status
» marks the 3rd indication for BLINCYTO
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Eli Lilly and Co(LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron(GERN.US)$ : Imetelstat
$Merck & Co(MRK.US)$ : V116
$Amgen(AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics(SRPT.US)$ : ELEVIDYS
$Merck & Co(MRK.US)$ : KEYTRUDA ...
$Eli Lilly and Co(LLY.US)$ easily 400+ Billion valuation from Obesity drug
$Novo-Nordisk A/S(NVO.US)$ 50-100 Billion if not wrong
$Amgen(AMGN.US)$ 20+ Billion on no data yet
$Bristol-Myers Squibb(BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro...
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...
This time around, FOMC nonaction and low jobs numbers helped push equities in the green, or it migh just be because April is finally over. My name is Kevin Travers, here are stories moving the market:
MOOVERS
$Amgen (AMGN.US)$'s stock soared 12% toward biggest gain in 15 years, adding more than 220 points to the...
No comment yet